Pfizer Says JAKs Have Their Place Despite Xeljanz Safety Issues

Management said it remains confident in Xeljanz and believes next-generation JAKs will be sufficiently differentiated. Pfizer's Vyndaqel and biosimilars businesses emerged as new blockbusters.